The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Novel non-KRAS G12C inhibitors in solid tumors
Alexander Spira, MD, Next Oncology-Virginia VCS, Fairfax, VA, provides an overview of non-KRAS G12C inhibitors for lung cancer and solid tumors, such as RMC-6236, which was assessed in the RMC-6236-001 trial (NCT05379985). In addition to lung cancer, the investigational pan-KRAS inhibitor was promising in pancreatic cancer, which has limited treatment options. KRAS G12D inhibitors under investigation include ASP3082 and RMC-9805. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
